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Abstract: Three new 6-methyl-2-oxo-1,2-dihydroquinoline-3-carbaldehyde-thiosemicarbazones-
N-4-substituted pro-ligands and their Cu(II) complexes (1, -NH2; 2, -NHMe; 3, -NHEt) have
been prepared and characterized. In both the X-ray structures of 1 and 3, two crystallographically
independent complex molecules were found that differ either in the nature of weakly metal-binding
species (water in 1a and nitrate in 1b) or in the co-ligand (water in 3a and methanol in 3b). Electron
Paramagnetic Resonance (EPR) measurements carried out on complexes 1 and 3 confirmed the
presence of such different species in the solution. The electrochemical behavior of the pro-ligands and
of the complexes was investigated, as well as their biological activity. Complexes 2 and 3 exhibited a
high cytotoxicity against human tumor cells and 3D spheroids derived from solid tumors, related to
the high cellular uptake. Complexes 2 and 3 also showed a high selectivity towards cancerous cell
lines with respect to non-cancerous cell lines and were able to circumvent cisplatin resistance. Via the
Transmission Electron Microscopy (TEM) imaging technique, preliminary insights into the biological
activity of copper complexes were obtained.
Keywords: copper thiosemicarbazones complexes; X ray crystal structure; cytotoxicity in 3D
spheroids; EPR and electrochemical measurements; TEM images
1. Introduction
Great interest has been reserved in the last decades to the chemistry of thiosemicarbazones
(TSC) of the type X-C(Z)=N-NH-C(=S)Y, where different combinations of X, Y and Z moieties have
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been introduced in the framework. This allows for the modulation of the lipophilic properties,
chelating abilities and steric hindrance, also by the presence of additional functional groups,
in order to attain an overall synergistic effect for their desired biological activity as such or
that of their metal complexes [1–12]. A wide range of medicinal effects of thiosemicarbazones
are well known (Chart 1): 1-methylisatin 3-TSC (Marboran, no longer produced as a drug) as
being antiviral [13], 4-acetylaminobenzaldehyde-TSC (amithiazone, [14,15]) for the treatment of
tuberculosis, 4-isopropylbenzaldehyde-TSC (cutisone [16]), 1,4-benzoquinone-amidinohydrazone-TSC
(ambazone, [17]), di-2-pyridylketone-4,4′-dimethyl-3-TSC [18] and 3-amino pyridine-2-carboxaldehyde-
TSC (Triapine, it has undergone Phase I and Phase II clinical trials, [19,20]) as potential antitumor drugs.
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Recently, some copper-TSC complexes have been tested in vivo on HL60 human xenographs [21]
and Ehlrich ascites carcinoma [22–24], showing a decrease in the weight loss and a significant increase
in the percentage life-span of tumor-bearing mice.
The biological activity of TSC metal complexes is associated with the chelating ability of TSC
ligands and their facility in inducing the perturbation of intracellular metal homeostasis (in particular of
iron [11,25,26] and copper [27,28]). By forming redox active complexes, they generate reactive oxygen
species (ROS) able to influence the activity of enzymes such as tyrosinase [29–31], topoisomerase [32],
kinase [33,34], ribonucleotide reductase [35] or metalloproteinase [36].
Thiosemicarbazones can act as NS [37] bidentate, NN′S [38] and ONS [39] tridentate or
ONN′S [40] tetradentate chelators, forming either neutral [41] or cationic [42,43], mononuclear [44,45]
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or polynuclear [46–48] systems with different metal ions. Complexes of V(IV) [49], Mn(II) [50],
Fe(III) [38,51], Co(III) [52], Ni(II) [53–56], Cu(II) [28,57,58], Zn(II) [48], Ga(III) [59,60], Ru(II/III) [61–69],
Pd(II) [70–74], In(III) [75], Re(I) [76,77], Pt(II) [78], Au(III) [79], Hg(II) [80], Ag(I) [81] and Sn(IV) [39]
exhibit higher cytotoxicity and antimicrobial effects compared with the corresponding pro-ligands [82].
The anticancer activity of the metal complexes has been exploited to develop new compounds able
to circumvent single and multidrug resistance [83]. In the attempt to achieve a structure/activity
relationship, it was reported that for the TSC systems, the NN′S chelators exhibit a superior activity
when compared to the ONS ones [1,28].
Quite recently, a Cu(II) hybrid system containing a polyoxometalate moiety and a
2-acetylpyrazine-TSC NN′S chelator was proven to exhibit antibacterial activity against Escherichia coli
and Staphilococcus aureus and a better cytotoxicity against human hepatic cancer cells (SMMC-7721)
than Mitoxantone, the current chemical anticancer drug, with an IC50 value of about 1.6 µg/mL [84].
In addition, bis(thiosemicarbazone) complexes of Cu(II) [85], Cu(I) [86] and Zn(II) [87] attracted
great attention owing to their antiproliferative activity; recently, a wide series of dissymmetrically
substituted bis(thiosemicarbazone) copper complexes, with different redox and lipophilic properties,
have been investigated as radiopharmaceuticals for positron emission tomography [88].
The influence of different anions (i.e., NO3− or SO42−) on the TSC coordination ability for Cu(II)
has also been investigated: it was observed that in the presence of the Cu(NO3)2·3H2O, binuclear
systems could be obtained which exhibited an intriguing anticancer activity through mitochondrial
apoptosis [89].
Some authors studied the coordination chemistry of TSC systems with different X moieties
(Chart 1), observing that neutral or cationic complexes with Ligand/Metal ratios of 1:1 [65,72,90],
2:2 [91], 1:2 [74] or 2:1 [52,56] could be achieved, and their biological activities in terms of interactions
with DNA via intercalation, antioxidant activity and cytotoxicity were investigated. For the water
soluble 6-methoxy-2-oxo-1,2-dihydroquinoline–carbaldehyde thiosemicarbazone Ni(II) complexes
bearing different NHR groups as the Y moiety (Chart 1), the biological activity depended on the nature
of the R, and the system with the NHPh group had a cytotoxicity higher than that of cisplatin [92].
In the case of 2-oxo-1,2-dihydroquinoline-3-carbaldehyde thiosemicarbazone Cu(II) complexes, neutral
compounds have been obtained when Y = NH2, NHMe or NHEt, whereas with Y = NHPh a cationic
complex was achieved, the latter showing improved biological activity [93].
Here, we report the synthesis, characterization and biological activity of three
6-methyl-2-oxo-1,2-dihydroquinoline-3-carbaldehyde-TSC compounds and their Cu(II) complexes
with the aim to evaluate the influence of X = C6H4CH3, compared with C6H4OCH3 analogues [90],
and of Y = NHR (R = H,Me,Et) on their physical, chemical and biological properties.
2. Results and Discussion
2.1. Synthesis and Characterization of the Pro-Ligands
H2L1, H2L2 and H2L3 have been prepared according to the procedure
previously reported in the literature (Scheme 1) [63,67,92,94] by condensation of
6-methyl-2-oxo-1,2-dihydroquinoline-3-carbaldehyde [95] with the corresponding thiosemicarbazides
in hot methanol. The compounds were obtained in high yields as yellow powders.
The absence of any ν(S-H) band in the 2700–2500 cm−1 region of the IR spectra excluded the
presence of thiol species [96] and indicated the thione conformation for the compounds in the solid
state. These results are in agreement with the theoretical calculations carried out on similar TSCs [97],
which have shown that the thione tautomeric forms are stable, even in the presence of a solvent
(MeOH). However, recent computational studies on 4-formylpyridine-TSC derivatives proved that
both the thiol and thione forms are stable [98].
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Scheme 1. The synthetic route of the ligands and Cu(II) complexes.
The 1H NMR spectra of H2L1 showed the presence of two distinct signals for –(C=S)NH2 protons
at 8.09 and 8.31 ppm, respectively, the latter presenting a NOESY correlation with the N(2)H proton at
11.64 ppm and suggested an E conformation. On the contrary, in the 1H NMR spectra of H2L2 and
H2L3 a NOESY correlation between N(3)H···CH3 and N(2)H···CH2CH3, respectively, was observed,
thus revealing different conformations in solution depending on the nature of the N(4) substituents [96]
(Figure 1).
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Figure 1. The Z(cis) and E(trans) rotamers of H2L1 (Y = NH2) and H2L2 (Y = NHCH3) (or H2L3,
Y = NHCH2CH3) [97].
As for the mass spectrometric data collected under ESI conditions, the [H3L]+ and [H2L+Na]+
ions were detected for all the compounds, together with ionic species formed by the loss of NH3,
H2NCH3 and H2NCH2CH3 from [H3L]+ (at m/z 244) and by the loss of H2S (at m/z 227, 241 and 255)
from [H3L1]+, [H3L2]+ and [H3L3]+, respectively. It is worth noting that the latter ionic species are
related to the metabolic pathways of TSCs compounds [3].
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2.2. Synthesis and Characterization of the Complexes
The copper complexes 1–3 were synthetized by the direct reaction of Cu(NO3)2 × 3H2O with
pro-ligand solutions. All the resulting mixtures gradually changed from blue to green, and by slow
solvent evaporation dark green powder and crystals were obtained and characterized. The reaction of
H2L1 with Cu(NO3)2.3H2O has been previously reported [99].
H2L1, H2L2 and H2L3 coordinated as ONS tridentate chelators in their neutral form lead to a
square planar environment around the Cu ion where the fourth coordination site is engaged with a
water (in 1a, 1b and 2) or a methanol molecule (in 3a and 3b). The coordination geometry around the
metal is completed by an additional water molecule (in 1a and 2), or one (in 3a and 3b) or two (in 1b)
nitrate anions, suggesting a possible facile substitution of the solvent ligands capable of promoting the
interaction with a biological substrate.
It is worth noting that in the case of the reaction of
6-methyl-2-oxo-1,2-dihydroquinoline-3-carbaldehyde TSC with [PdCl2(PPh3)2] [100], the coordination
mode depended on the nature of the Y substituents: tridentate ONS chelation when Y = NH2 (as in the
present case) and bidentate NS chelation for Y = NHR (R = Me, Et, Ph).
The infrared spectra showed a decrease of the carbonyl stretching of the TCS ligand upon
coordination, which was particularly evident for compounds 1 and 2, together with a decrease of the
C=S stretching vibration by 20 cm−1. The further appearance of bands attributed to Cu-O (523–525 cm−1)
and to Cu-N (463–469 cm−1) confirmed the ONS coordination [101].
The mass spectra of the complexes revealed the presence of the [HLCu]+ ions as base peaks,
together with oligomeric ionic species, as often observed under ESI conditions [58,102].
The Continuous-Wave EPR (CW-EPR) spectra of 1 and 3 in the frozen matrix at 80 K are reported
in Figure 2. The CW-EPR spectra of the Cu(II) complexes were characterized by a quartet of lines at
low-field (the so-called parallel region), and a strong line at the higher field (perpendicular region).
The parallel region was the most informative: the position of the quartet (related to the gzz parameter)
and the distance between the lines (the Azz parameter) are very sensitive, even to small changes in
the copper coordination. In agreement with the X-ray data, the spectrum of 1 (Figure 2, left) showed
the occurrence of two detectable Cu(II) complexes with different coordinations. A well-matched
simulated spectrum could be obtained, taking into account two Cu(II) species: one with gzz = 2.388 and
Azz = 410 MHz (quartet marked by black vertical lines) and the other with gzz = 2.260, Azz = 520 MHz
(quartet marked by dotted vertical lines). The latter presented a reduced gzz with an increased Azz
with respect to the former, which was indicative of an increased covalent bonding and/or a decreased
complex charge, in agreement with the X-ray determination that showed that the copper ion coordinated
two water molecules in 1a and one water molecule and one nitrate anion in 1b. The EPR parameters
for the first species (Table 1) were consistent with ONS donor Cu(II) complexes, and matched well with
the complexes with two water molecules coordinated to the Cu(II) [103–105], and we could therefore
assign it to 1a. The second species had EPR parameters consistent with an ONS donor Cu(II) complex
and could be attributed to 1b. The gzz/Azz ratio has also been related to a deviation from square planar
geometry [106], and this ratio was larger in 1a than in 1b, as revealed by the X-ray structure.
The EPR spectrum of 3 (Figure 2, right) showed a different pattern: apart from the presence of
one species presenting very similar parameters to those of 1a (quartet marked by black vertical lines)
and another (marked by gray vertical lines) not very different from those found for 1b, a third entity
(in very small amounts) with a smaller gzz and larger Azz was also identified. Taking into consideration
the resemblance of the EPR data and of the XRD structures, we could tentatively assign the species
with parameters not very different from 1b, to the entity 3b (in fact, the g value was larger, in this
case, but the gzz/Azz ratio was similar), both actually presenting a similar coordination environment.
However, the EPR parameters in the sample of 3 identical to those of 1a could hardly be assigned to the
XRD structure of 3a, in view of the observed coordination distortion resulting from the steric influence
of methanol. A tetrahedral Cu(II) configuration is easier in a crystalline or constrained environment,
but it is unlikely to occur in solution, where Cu(II) prefers octahedral or square planar configurations.
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Since the EPR measurements were performed in ethanol, we could speculate that 3a “relaxed” towards
an octahedral or square planar structure (similar to 1a). Further investigations through ENDOR will
be carried out to clarify this point.
Table 1. Parameters obtained from the simulations for the CW-EPR spectra of samples 1 and 3 in
ethanol at 80 K. Hyperfine constants Axx, Ayy and Azz are in cm−1.
Assignment gzz Azz gxx gyy Axx Ayy
1a 2.388 137 × 10−4 2.07 2.08 3.3 × 10−4 3.3 × 10−4
1b 2.260 173 × 10−4 2.07 2.10 5.0 × 10−4 5.0 × 10−4
3a 2.385 147 × 10−4 2.01 2.08 4.0 × 10−4 4.0 × 10−4
3b 2.350 182 × 10−4 2.07 2.10 5.0 × 10−4 5.0 × 10−4
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2.3. Electrochemical Properties
The cyclic voltammetry studies were performed in DMSO/0.2 M [NBu4][BF4] solutions, at ambient
temperature, in a three electrode cell and using a 0.5 mm diameter platinum disc working electrode.
No oxidation waves were detected for H2L1-H2L3 pro-ligands in the available potential window, but
they presented, at a scan rate of 0.2 V·s−1, an irreversible cathodic wave (wave L, Figure 3 and Figure
S1 (in the Supplementary Material file); Table 2) at a potential value of −1.56 V vs. SCE (Table 2), which
was insensitive to the structural differences (Y moiety, see Chart 1) of the compounds. No anodic
processes were detected for H2L1-H2L3 in the available potential window.
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Table 2. Cyclic voltammetry data 1 for the thiosemicarbazone pro-ligands and their Cu(II) complexes.
Compound Cathodic Peak Potential Anodic Peak Potential
3
Lred Ired 2 A Iox
H2L1
H2L2
H2L3
−1.56
1 −1.59 −0.26 −0.05 0.36
2 −1.56 −0.32 −0.05 0.27
3 −1.56 −0.31 −0.07 0.24
1 Potential values (in Volt ± 0.02) relative to SCE, measured by CV at a Pt electrode in DMSO/0.2 M [NBu4][BF4]
at 0.2 V·s−1. 2 Broad wave which split into two at low scan rates (see text). 3 Redox processes detected only
upon reversing the potential scan direction at a low cathodic potential limit, or after the formation of wave Ired at
sufficiently low scan rates.
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Figure 3. Cyclic voltammogram for H2L2 (C = 2.00 × 10−3 M) in [NBu4][BF4] 0.2 M in DMSO at a
platinum disc working electrode (d = 0.5 mm) and at a scan rate of 0.2 V.s−1. The arrow indicates the
cathodic initial scan direction.
Wave Lred was also detected in the derived Cu(II) complexes 1–3 at the same potential value
(Figure 4 and Figure S2), therefore suggesting that the redox process was located far off from the
influence of the metal center. In addition, the Cu(II) compounds presented, at the scan rate of
200 mV·s−1, a broad reduction wave (wave Ired, Figure 4, top; Figure S2) between −0.26 and −0.32 V
vs. SCE (Table 2), which was believed to involve the overlapped stepwise CuII→CuI and CuI→Cu0
reductions. Although at 0.2 V.s−1 the two cathodic processes were undifferentiated, they became
evidently separated at lower scan rates (Figure 4, bottom), and a novel wave, B, (Figure 4, bottom) was
detected at potentials of ca. −0.40 V vs. SCE.
Upon reversing the potential scan direction after the formation of wave Lred, two anodic waves
were observed, wave A and wave Iox (Figure 4, top; Figure S2), assigned to the Cu0→CuI and CuI→CuII
oxidations, respectively. Such anodic waves (A and Iox) could also be detected upon reversing the
potential scan direction after the formation of wave Ired, provided the scan rate of the potential was
sufficiently low, in particular for complex 2 (Figure 4, relate the top offset CV with the bottom one;
compare with Figure S2). In view of the dicationic nature of compound 2, its wave Ired potential was
expected to be at a less negative value as compared to those of compounds 1 and 3. The difficulty in
rationalizing the redox potential values may be related not only to the broadness of this wave but also
to the possible presence of different species in solution (see Sections 2.2 and 2.3).
Our results contrast with those obtained for Cu(II) complexes with other TSC derivatives, for
which only a cathodic wave corresponding to the quasi-reversible CuII→CuI process was detected [107]
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at potential ranges from −0.68 to −0.49 V vs. SCE. Such reports contrast with our results, for which
the stepwise reduction of CuII to Cu0 was observed at considerably lower negative potential values.
This fact could be relevant from the biological point of view (see below). No rationalization between the
cathodic and derived anodic potentials for 1–3 and the amine (Y) group could be achieved, in agreement
with what was previously reported for other Cu(II) TSC compounds [108].
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Figure 4. Cyclic voltammogram for complex 2 (C = 2.98 x 10−3 M) in [NBu4][BF4] 0.2 M in DMSO at a
platinum disc working electrode (d = 0.5 mm), at 0.2 V·s−1 (top, including offset CV) and at 0.05 V·s−1
(bottom). The arrows indicate the cathodic initial scan direction.
3. Crystal Structures of the Complexes 1, 2 and 3
Suitable crystals of the Cu(II) complexes of the ligands [H2L1] (complex 1), [H2L2] (complex 2) and
[H2L3] (complex 3) were obtained by sl w evaporation from diluted methanol solutions. The im ediate
coordination spher around the Cu c nters in all these complexes is the sa e with the s bstituted
thiosemicarbazones acting as ONS tridentate ligands. However, the different substitutions on the
TSC ligands (-NH2 in 1, -NHMe in 2 and –NHEt in 3) have an influence on the hydrogen-bond
network and the resulting molecular packing. In all the complexes, the TSC ligand is flat (max.
deviations fr m planarity based on the relevant lsq-planes ca. ± 0.03 Å). In two cases (compounds 1
and 3), the asymmetric unit contains two in ependent molecules with different overall coordinations.
In complex 2, only one type of metal compound was located, so we start with its discussion. The metal
oxidation state was the same in all three compounds, in agreement with the EPR data.
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3.1. Solid State Structure of 2
Figure 5 shows an Ortep view of 2; selected bond lengths and angles are reported in Table 3, and
an extended list of bond lengths and angles is given in Tables S5 and S6.
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Figure 5. Ortep view of the cation in complex 2. (Ellipsoids drawn at 50% probability; the numbering
scheme used is just for comparison purposes in the following tables).
The presence of two NO3− counterions unambiguously defines the metal oxidation state.
The immediate coordination sphere consisted of the N, O, S atoms of the TSC ligand and the O
atom of a water molecule (Cu-Ow1 1.928(3) Å); these ligands define a square planar geometry
(Supplementary Materials, Table S7). A second clathrated H2O molecule (Cu-Ow2 2.226(4) Å) in an
apical position resulted in a pseudo square-pyramidal environment. The Cu–ligand bond distances
and angles are in the expected range and comparable with those of related structures [109].
There is a complex network of hydrogen bonds (Figures S4 and S6) involving the nitrate
counter-ions as acceptors (A) and the O, N atoms of 2 as donors (D), with the D· · ·A distances in
the range 2.6–3.1 Å. Moreover, weak pi-stacking interactions between the quinolinic rings could be
observed (Figure S4), with centroid· · · centroid distances of ca. 3.8 Å.
3.2. Solid State Structure of 1
The crystal structure determination revealed the presence of two independent Cu(II) cations in the
unit cell (1a and 1b, respectively), four nitrate ions and four clathrated water molecules. The immediate
coordination sphere around the Cu center in 1a and 1b is identical to that found in 2 (Figure 6), with
comparable distances and angles. However, while in 1a even the weakly bound water molecule is
present, in 1b (Figure 7) there are weak interactions with oxygen atoms from two nitrates (2.695(4)
Å and 2.525(4) Å) giving rise to a pseudo-octahedral copper environment. Moreover, the Cu-ON1
separation in 1b (Cu–O 2.582(3) Å) was approximately equal to that found in the Cu–L complex
(L = 2-oxo-1,2-dihydrobenzo[h]quinoline-3-carbaldehyde(2′-hydroxybenzoyl)hydrazine) [109], with a
similar six-coordinated copper arrangement. The few small but statistically significant differences in
bond lengths and angles (Table 3) around the two Cu centers (e.g., Cu–S at 2.266(2) Å in 2, 2.289(2) Å in
1b and 2.278(1) Å in 1a) may be explained by the above-mentioned different overall environments
and crystal packings. The intricate hydrogen-bond network (with donor· · · acceptor distances in
the 2.6–2.9 Å range) involving the counter-ions and the O, N donors of the ligands is shown in
Figures S10–S12. Due to the presence of the NH2 moiety in 1 acting as an H donor, the molecular
packings here are quite different from those in 2 (Figure S11).
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Table 3. Selected Bond Lengths (Å) and Angles (deg) for 2 and 1.
2 1a * 1b *
Cu1–O1 1.948(3) 1.973(3) 1.946(3)
Cu1–S1 2.266(2) 2.289(2) 2.278(1)
Cu1–N2 1.977(3) 1.975(3) 1.969(3)
Cu1–Ow1 1.928(3) 1.961(2) 1.943(3)
Cu1–Ow2 2.226(4) 2.254(2)
Cu1–ON1 2.695(4)
Cu1–ON2 2.525(4)
N2–Cu1–Ow2 96.6(1) 100.7(1) 88.5(3)
Ow1–Cu1–Ow2 90.9(2) 97.0(1)) 82.2(2)
Ow1–Cu1–ON1 113.2(2)
N2–Cu1–Ow1 172.4(1) 169.2(1) 170.6(1)
ON1–Cu1–ON2 158.1(2)
* 1a and 1b refer to the two independent molecules in the unit cell of compound 1.
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3.3. Solid State Structure of 3
The crystal structure determination revealed the presence of two independent molecules in the
asymmetric unit (Figure 8 (3a) and Figure 9 (3b)), four nitrate ions and a clathrated water molecule.
Selected bond lengths and angles are listed in Table 4; an extended list of bond lengths and angles
is given in Table S10. In both cations, the metal centers are bonded to the three donor atoms of the
HL3 ligand (i.e., S1, O1 and N2), while the fourth position of the slightly distorted square planar
geometry is taken by a CH3OH molecule in 3a and an H2O ligand in 3b; a weakly interacting nitrate
(at 2.318(3) Å and 2.388(3) Å, respectively) completed the coordination sphere. The bond lengths and
angles involving the metal centers are in the expected range, comparable to those found in compounds
1 and 2. The distances for the Cu-Om1 and Cu-Ow1 bonds fall at 1.989(3) and 1.931(3) Å, respectively.
The Cu-Ow1 and Cu-ON1 separations in 3 are close to those found in the copper complex with
2-oxo-1,2-dihydrobenzo[h]quinoline-3-carbaldehyde(2′-hydroxybenzoyl)hydrazone (1.915(2) Å and
2.332(2) Å, respectively) [109]. The other bond lengths and angles are unexceptional. The differences
in the geometrical parameters (Table 4) are easily accounted for by the different second-coordination
sphere weak interactions or the aquo vs. methanol ligand coordination.
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Table 4. Selected bond lengths (Å) and angles (deg) for 3.
3a(Cu1) * 3b(Cu2) *
Cu–O1 1.930(3) 1.929(3)
Cu–S1 2.263(1) 2.258(1)
Cu–N2 1.986(3) 1.977(3)
Cu–Om1 1.989(3)
Cu–Ow1 1.931(3)
Cu–ON1 2.318(3) 2.388(3)
N2–Cu–O1 90.8(1) 91.3(1)
N2–Cu–S1 87.0(1) 87.4(1)
N2–Cu–ON1 122.3(1) 86.4(1)
ON1–Cu–Om1 80.1(1)
ON1–Cu–Ow1 91.7(1)
S1–Cu–ON1 90.86(8) 99.93(8)
N2–Cu–Om1 157.6(1)
N2–Cu–Ow1 178.0(1)
S1–Cu–O1 177.16(9) 168.12(9)
* 3a and 3b refer to the two independent molecules in the unit cell of compound 3, shown in Figures 8
and 9, respectively.
4. Biological Activity
The in vitro antiproliferative activities of the copper(II) complexes 1–3 and of the corresponding
pro-ligands (H2L1, H2L2 and H2L3) were evaluated against a panel of human tumor cell lines
derived from solid tumors. The cytotoxicity parameters, expressed as IC50 (the median growth
inhibitory concentration calculated from dose–survival curves), obtained after 72 h exposure, are
listed in Table 5. Cell lines representative of colon (HCT-15), lung (A549) and pancreatic (BxPC3
and PSN-1) cancers, along with melanoma (A375), have been included. For comparison purposes,
the cytotoxicity of cisplatin, the most widely used metal-based anticancer drug, was assessed under
the same experimental conditions.
Table 5. Cytotoxicity studies.
IC50(µM) ± S.D.
Compounds HCT-15 A549 BxPC3 PSN-1 A375
1 8.4 ± 1.7 6.8 ± 1.3 7.8 ± 0.5 9.2 ± 1.6 0.6 ± 0.2
H2L1 >25 >50 16.8 ± 2.6 18.3 ± 2.8 17.5 ± 3.2
2 2.6 ± 1.2 5.6 ± 0.5 0.1 ± 0.08 4.6 ± 2.0 0.027 ± 0.005
H2L2 >25 >50 >25 >100 >25
3 1.7 ± 1.5 3.2 ± 0.6 0.3 ± 0.2 5.3 ± 0.3 0.031 ± 0.001
H2L3 23.4 ± 1.0 >25 >25 >100 >100
cisplatin 15.5 ± 3.8 6.9 ± 2.1 13.9 ± 5.9 13.5 ± 4.1 1.3 ± 0.6
The IC50 values were calculated by the four parameter logistic model (p < 0.05). Cells (3–8·103·mL−1) were treated
for 72 h with increasing concentrations of tested compounds dissolved in DMSO (Cytotoxicity was assessed by MTT
test). S.D. = standard deviation.
The uncoordinated ligands proved to be scarcely effective in decreasing the cancer cell viability
(the average IC50 values were over 25 or 50 µM), whereas all Cu(II) complexes elicited IC50 values
ranging from sub-micromolar to low micromolar levels (0.02–8.4 µM).
TSC Cu(II)complexes showed a higher potency than cisplatin against all the tested cancer cell lines.
Compounds 2 and 3 showed a similar cytotoxicity profile, whereas 1 was endowed with the weakest
in vitro antiproliferative effect. However, on average, complex 3 was the most effective derivative,
showing IC50 values about five times lower than those calculated for cisplatin and about two times
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higher than those calculated for 1. Notably, against human pancreatic cancer BxPC3 cells, complex 3
promoted a growth inhibitory effect about 46 times higher than that of cisplatin. It is worth noting that
all Cu(II) complexes showed a prominent cytotoxicity towards human melanoma A375 cells. Tested
against this cell line, complexes 2 and 3 elicited nanomolar IC50 values, attesting to a cytotoxicity
roughly 56 times higher than that of the reference metal-based drug. For a comparison, the IC50
values against A549 cell lines for complexes 1–3 resulted in being much lower than those for related
thiosemicarbazone complexes bearing Pd(II) [47], Co(III) [52] or Ni(II) [91], respectively.
The antiproliferative activity of the Cu(II) TSC complexes 1–3 was also investigated in two pairs
of additional cell lines, including cisplatin-sensitive and -resistant human ovarian adenocarcinoma
2008/C13* cells, and oxaliplatin-sensitive and -resistant human colon carcinoma LoVo/LoVo-OXP cells.
C13* cells and LoVo-OXP cells were suitably selected after a chronic treatment with the selected drug
according to established protocols. Several mechanisms are known to cause the resistance to cisplatin of
C13* cancer cells; these include (i) a reduced intracellular drug accumulation [110], (ii) high cellular levels
of glutathione and metallothioneins [111], (iii) the enhanced repair of platinum-DNA adducts [112],
and (iv) an overexpression of the Trx system [113]. On the other hand, oxaliplatin-resistant cells are
mainly characterized by reduced drug accumulation and raised thiol levels whereas an increased
tolerance to DNA platination seems to be less evident [114].
Cytotoxicity was assessed after 72 h of drug treatment by an MTT test, and the IC50 and RF values
(RF = resistance factor, defined as the ratio of the IC50 of resistant cells over the IC50 of sensitive ones)
are reported in Table 6. All new TSC Cu(II) complexes exhibited a similar cytotoxic potency both on
sensitive and resistant cells, thus proving to be capable of overcoming both cisplatin and oxaliplatin
resistance. Again, complex 3 was the most effective compound, showing in these cancer cell lines IC50
values in the low micromolar range.
Table 6. Cross-resistance profiles.
IC50(µM) ± S.D.
Compounds 2008 C13* R.F. LoVo LoVo-OXP R.F.
1 9.7 ± 3.3 6.7 ± 1.2 0.7 0.7 ± 0.07 1.2 ± 0.6 1.8
2 11.2 ± 2.0 8.5 ± 3.5 0.8 1.9 ± 0.6 2.0 ± 0.04 1.1
3 2.8 ± 0.9 0.9 ± 0.7 0.3 0.7 ± 0.5 1.1 ± 0.1 1.6
cisplatin 2.1 ± 0.6 26.9 ± 4.3 12.8
oxaliplatin 3.1 ± 0.3 53.4 ± 0.8 17.2
The IC50 values were calculated by the four parameter logistic model (p < 0.05). Cells (3–8·103·mL−1) were treated
for 72 h with increasing concentrations of tested compounds dissolved in DMSO. Cytotoxicity was assessed by MTT
test. R.F. = IC50 (resistant subline)/IC50 (wild-type cells). S.D. = standard deviation.
As one of the main drawbacks of chemotherapeutic drugs is the possible toxic effect toward
non-cancerous cells, we measured the cytotoxicity of 1–3 against non-cancerous cells (HEK293) and
calculated the selectivity index (SI) by dividing the IC50 value in non-cancerous cells by that in the
most sensitive A375 cancer cells. The cytotoxicity data for HEK293 cells and the selectivity indices are
reported in Table 7. All TSC Cu(II) complexes showed IC50 values in the micromolar range against
HEK293 non-cancerous cells. Despite the fact that a general selectivity towards cancer cells could not
be attributed to complexes 1–3, when considering A375 cancer cells a preferential cytotoxicity against
tumor cells became evident. The SI A375 calculated for complexes 2 and 3 were roughly three-fold
higher than that calculated for cisplatin, attesting to the preferential cytotoxicity of both complexes
towards human melanoma cells.
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Table 7. Cytotoxicity against non-cancerous cells.
Compounds HEK293IC50(µM) ± S.D.
SI
A375
1 3.9 ± 3.1 6.5
2 1.3 ± 0.8 41.9
3 1.1 ± 0.2 47.8
cisplatin 21.6 ± 3.5 16.6
The IC50 values were calculated by a four parameter logistic model (p < 0.05). Cells (5·103·mL−1) were treated for 72
h with increasing concentrations of tested compounds dissolved in DMSO. Cytotoxicity was assessed by MTT test.
SI A375 = IC50 HEK293 non-cancer cells/IC50 A375 cancer cells. S.D. = standard deviation.
The Cu(II) compounds 1–3 were also screened against 3D spheroids of colon cancer cells (HCT-15)
and melanoma cells (A375). 3D cell cultures, comprising cancer cells in various cell growth stages,
possess several features that more closely mimic the heterogeneity and complexity of in vivo tumors,
being potentially more predictive for in vivo results than conventional 2D cell cultures [115]. The cancer
spheroids were treated with Cu(II) complexes or cisplatin for 72 h, and the cell viability was assessed by
means of the acid phosphatase (APH) assay (Table 8). Compounds 1–3 were markedly more effective
than cisplatin against both 3D HCT-15 and A375 cultures. In particular, complex 2 was approximately
eight- and four-fold more effective than cisplatin against HCT-15 and A375 cancer cell spheroids.
These results clearly confirm the in vitro antiproliferative potential of these copper(II) TSC complexes.
Table 8. Cytotoxicity towards human cancer cell spheroids.
IC50(µM) ± S.D.
Compounds HCT-15 A375
1 14.9 ± 2.3 18.6 ± 3.9
2 6.50 ± 0.80 7.6 ± 1.7
3 16.0 ± 2.8 11.3 ± 2.5
cisplatin 54.75 ± 1.26 32.8 ± 6.1
Spheroids (3·103 cells/well) were treated for 72 h with increasing concentrations of tested compounds. The growth
inhibitory effect was evaluated by means of the APH assay. IC50 values were calculated from the dose-survival
curves by the four-parameter logistic model (p < 0.05). S.D. = standard deviation.
As the biological activity of the compounds is determined by the extent of cellular accumulation, in
the attempt to correlate the cytotoxicity potency with the ability of the tested complexes to enter cancer
cells, we performed cellular uptake studies in A375 human melanoma cells. Cells were treated with 2
µM of copper complexes for 12 or 24 h, and the cellular copper content was quantified. The results,
expressed as ng of Cu per 106 cells, have been summarized in Figure 10.
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complexes for 12 or 24 h, and the cellular copper content was detected by a GF-AAS analysis. Error bars
indicate the standard deviation. ** p < 0.01.
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All complexes were able to accumulate in a time-dependent manner, and compounds 2 and
3 were more efficient with respect to complex 1 in crossing the cellular periplasmic membrane.
In addition, no saturation of the uptake was observed, therefore suggesting that carrier-mediated
transport mechanisms can be excluded. Interestingly, by matching the cytotoxic activity values with
the cellular uptake data recorded at 24 h, a direct and linear correlation was evidenced (R2 = 0.78, data
not shown).
Since the ′60s, DNA has been referenced as the main molecular target for various copper(II)
complexes in many studies [28]. In addition, various TSCs have been recently recognized as DNA
binding compounds [116]. On this basis, we evaluated the ability of Cu(II) complexes 1–3 to interact
with DNA. Unfortunately, spectroscopic studies such as UV-titration and EB competition experiments
with isolated DNA provided inconsistent results due to the very low solubility of tested complexes in
Tris-HCl or other buffer systems. Similarly, DNA plasmid cleavage studies were hampered by the
scarce solubility of tested complexes in serum-free media. Hence, the ability to induce DNA damage
of compounds 2 and 3 was tested in intact cells by using the DNA damage ELISA kit. The results
concerning A375 cancer cells treated with IC50 concentrations of 2 and 3 for 24 h have been reported
in Figure 11 (left). A375 cancer cells treated with 2 and 3 showed a consistent increase (about 40%
and 36%, respectively) in mono- and oligo-nucleosome formations, thus confirming the ability of the
complexes to induce the fragmentation of nuclear DNA.
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Figure 11. Left: frag entation. 375 cells ere treated for 24 h ith IC50 values of tested
co pounds and were then processed for nucleosome formation. The error bars indicate the S.D. Right:
ROS production. A375 cells were pre-incubated in PBS/10 mM glucose medium for 20 min at 37 ◦C in
the presence of 10 µM CM-H2DCFDA and were then treated with IC50 of compounds 1–3. The error
bars indicate the S.D. ** p < 0.01; * p < 0.05.
It has been widely reported that TSC copper complexes may catalyze hydrogen peroxide in the
form of Fenton-like reactions inside the cell to produce ROS, thus altering cellular redox homeostasis
and driving cells towards oxidative stress [117]. Based on this, we evaluated the intracellular levels of
ROS in A375 cells after treatment with the copper complexes. As shown in Figure 11 (right), treatment
of human melanoma cells with compounds 1–3 led to a very slight increase of the intracellular ROS
accumulation. In particular, compound 2 was the most effective. The level of the generated ROS
species was, however, significantly lower than that of antimycin, a classic inhibitor of the mitochondrial
respiratory chain at the level of complex III.
Finally, in order to characterize the cellular morphological changes induced by the new Cu(II) TSC
compounds, we observed treated A375 cancer cells using transmission electron microscopy (TEM),
a valuable tool for investigating cells and their alterations at the ultrastructural level. Figure 12
shows representative TEM images of A375 cells after incubation for 48 h with IC50 doses of 2 and
3. Cells treated with copper-TSC derivatives exhibited the characteristic ultrastructural features
of apoptosis, such as cell shrinkage, chromatin condensation and formation of apoptotic bodies
(Figure 12c–f with a,b control cells). However, mitochondria appeared to be quite conserved in terms
Molecules 2020, 25, 1868 16 of 31
of shape and internal structures, with minimal evidence of swelling features (increase in size and
decrease in turbidity).
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5. Materials and Methods
5.1. General
All reagents and solvents were commercially available and used without further purification.
6-methyl-2-oxo-1,2-dihydroquinoline-3-carbaldehyde was prepared according to the procedures
previously reported in the literature [94].
The infrared spectra were obtained on a Spectrum 100 FT IR Spectrophotometer (Perkin-Elmer
Italia, Milan, Italy) (KBr disks) in the range of 4000–400 cm−1; the wavenumbers (v) are given in cm−1.
The electronic spectra of the complexes were recorded with a Jasco V-630 spectrophotometer
(Jasco Europe, Milan, Italy) using DMSO as the solvent. Emission spectra were measured using a Jasco
FP 6600 spectrofluorometer.
Elemental analyses (C, H, N, S) were performed on a Vario EL III Elementar analyzer instrument
(Elementar Italia, Italy, Milan).
1H and 13C NMR spectra were obtained at 298 K on a AMX 600 NMR (Bruker, Milan, Italy)
operating at 600.13 and 150.9 MHz, respectively; δ values (ppm) are relative to Me4Si for 1H and
13C. Suitable integral values for the proton spectra were obtained with a pre-scan delay of 10 s.
The assignments of the proton resonances were performed by standard homonuclear chemical shift
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correlations (COSY, NOESY, TOCSY). The 13C resonances were attributed through 2D-heterocorrelated
COSY experiments: the heteronuclear multiple quantum correlation (HMQC) with bilinear rotation
decoupling [118] and quadrature along F1 were achieved using the time proportional phase increment
method for the hydrogen-bonded carbon atoms, and the heteronuclear multiple bond correlation
(HMBC) [119,120] for the quaternary ones.
The CW-EPR spectra were acquired on a ECS106 instrument (Bruker, Milan, Italy), equipped
with a cryostat for low temperature measurements. The samples were prepared by dissolving the
complexes HL1Cu and HL3Cu in ethanol (conc. 1 × 10−3 M), followed by quick freezing in liquid
nitrogen. The acquisition parameters were: field sweep 70.0 mT, center field 305.0 mT, microwave
power 743 µW, modulation amplitude 0.1 mT and microwave frequency 9.679 GHz.
Cyclic voltammetric studies were performed at ambient temperature on an EG&G PAR 273A
potentiostat/galvanostat connected to a computer through a general-purpose interface bus (GPIB)
interface. A three electrode cell was used, filled with 5 mL DMSO solutions of 0.2 M [NBu4][BF4]
electrolyte, using a platinum disc (0.5 mm diameter) as the working electrode. A platinum auxiliary
electrode was employed, and the potential was controlled vs. a Luggin capillary connected to a silver
wire pseudo reference. Redox potential values were measured using ferrocene as the internal standard,
for which the Eox1/2 value of 0.44 V vs. SCE was measured under the same experimental conditions,
at 0.2 V·s−1, and using the saturated calomel electrode (SCE) as reference.
The ESI MS analyses were performed using a Finningan LCQ-Duo ion-trap instrument (Thermo
Fischer Scientific, Milan, Italy), operating in positive ion mode (sheath gas flow N2 30 a.u., source
voltage 4.0 kV, capillary voltage 21 V, capillary temperature 200 ◦C). The He pressure inside the trap
was kept constant. The pressure, directly read by an ion gauge (in the absence of the N2 stream), was
1.33 × 10−5 Torr. Sample solutions were prepared by dissolving the compounds (3 mg) in MeOH (5 mL)
and diluting 1 mL of the solution in MeOH (5 mL) immediately before analysis.
5.2. Preparation of the Compounds
5.2.1. Synthesis of 6-Methyl-2-oxo-1,2-dihydro-quinoline-3-carbaldehyde thiosemicarbazone (H2L1)
Thiosemicarbazide (0.91 g, 0.01 mol) dissolved in warm methanol (50 mL) was added to a methanol
solution (50 mL) containing 6-methyl-2-oxo-1,2-dihydroquinoline-3-carbaldehyde (1.87 g, 0.01 mol).
The mixture was refluxed for an hour, during which a yellow precipitate was formed. The reaction
mixture was then cooled to room temperature, and the solid was filtered, washed with methanol and
dried under vacuum. Yield 2.50 g (90%). MP: 248–250 ◦C. Elemental Analysis Anal. C 51.72%; H 4.97%,
N 19.97%, S 11.41%. Calcd. for: C12H12N4OS·H2O (MW 278.33) C 51.78%, H 5.07%, N 20.13%, S 11.52%.
UV-visible (DMSO; λmax, nm): 262, 352, 405 (л→л*, n→л*). IR (KBr, cm−1): 3435, 3164 (s) ν(NH); 3281
(s) ν(NH2); 1658 (s) ν(C=O); 1598, 1564 (s) ν(C=N) + ν(C=C); 845 (m) ν(C=S). 1H NMR (DMSO-d6,
600 MHz) δ 11.64 (1H, s, N(2)-H), 11.94 (1H, s, N(3)-H), 8.31 and 8.09 (2H, m, NH2), 8.29 (1H, s, C(1)-H),
8.71 (1H, s, C(6)-H), 7.24 (1H, d, J = 8.4 Hz, C(7)-H), 7.37 (1H,dd, J = 8.4 Hz, J = 1.8 Hz,C(8)-H), 7.43
(1H,d, J = 1.8 Hz, C(10)-H), 2.36 (3H, s, C(11)-H). 13C{1H} NMR (DMSO-d6, 600 MHz) δ 137.3 (C-1),
125.7 (C-2), 161.3 (C-3), 137.4 (C-4), 116.7 (C-5), 135.3 (C-6), 115.6 (C-7), 132.7 (C-8), 132.8 (C-9), 128.3
(C-10), 20.4 (C-11), 161.3 (C-12). 15N NMR (DMSO-d6, 600 MHz) δ 320 (s, N(1)); 173 (d, J = 95 Hz,
N(2)H), 151 (d, J = 90 Hz, N(3)H), 109 (t, J = 90 Hz, N(4)H). ESI (H2L1 = C12H12N4OS, MW 260.31)
m/z 261 [H3L1]+ (30), 283 [H2L1Na]+ (10), 244 [H3L1 - NH3]+ (20), 266 [H2L1Na–NH3]+ (55), 227
[H3L1-H2S]+ (40), 803 [3H2L1Na]+ (20), 845 [C36H32N12O3S3Na3]+(80), 915 [C44H27N12O4S4]+ (100).
5.2.2. Synthesis of 6-Methyl-2-oxo-1,2-dihydroquinoline-3-carbaldehyde-4N-methylthiosemicarbazone
(H2L2)
It was prepared using the same procedure as described for H2L1 with 4-methyl-3-thiosemicarbazide
(1.052 g, 0.01 mol) and 6-methyl-2-oxo-1,2-dihydroquinoline-3-carbaldehyde (1.87 g, 0.01 mol). A yellow
product was obtained. Yield 2.30 g (84%). MP: 261–263 ◦C. Elemental Analysis Anal C 56.83%, H 5.10%,
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N 20.28%, S 11.63%. Calcd. for C13H14N4OS (MW 274.32) C 56.91%, H 5.14%, N 20.49%, S, 11.69%.
UV-visible (DMSO; λmax, nm): 265, 354, 408 (л→л*, n→л*). IR (KBr, cm−1) 3374, 3167 (s) ν(NH); 1651
(s) ν(C=O); 1556, 1602 (s) ν(C=N) + ν(C=C); 849 (m) ν(C=S). 1H NMR (DMSO-d6, 600 MHz; atoms
labeling according to X-Ray structure of compound 2) δ 11.71 (1H, s, N(3)-H), 11.95 (1H, s, N(1)-H),
8.60 (1H, s, N(4)-H), 8.29 (1H, s, C(1)-H), 8.63 (1H, s, C(6)-H), 7.22 (1H,d, J = 8.2 Hz, C(8)-H), 7.37
(1H,d, J = 8.2 Hz, C(7)-H), 7.40 (1H, s, C(5)-H), 2.37 (3H, s, C(11)-H), 3.07 (3H, s, C(13)-H). 13C{1H}
NMR (DMSO-d6, 600 MHz) δ 136.9(C-1), 125.8 (C-2), 161.4 (C-10), 134.9 (C-3), 137.4 (C-4), 134.9 (C-9),
115.6 (C-8), 132.8 (C-7), 131.8 (C-6), 128.3 (C-5), 20.9 (C-11), 178.1 (C-12), 31.3 (C-13). ESI(H2L2 =
C13H14N4OS) m/z 275 [H3L2]+ (60), 297 [H2L2Na]+ (100), 244 [H3L2–NH2Me]+ (50), 241 [H3L2-H2S]+
(10), 571 [2H2L2Na]+ (40), 1119 [4H2L2Na]+ (50), 1393 [5H2L2Na]+ (65), 1667 [6H2L2Na]+ (80), 1941
[7H2L2Na]+ (65), 705 [C40H49N8O4]+ (30), 979 [C40H49N8O4+H2L2]+ (20), 1253 [C40H49N8O4+2H2L2]+
(20), 1527 [C40H49N8O4+3H2L2]+ (30), 1801 [C40H49N8O4+4H2L2]+ (30).
5.2.3. Synthesis of 6-Methyl-2-oxo-1,2-dihydro-quinoline-3-carbaldehyde-4N-ethylthiosemicarbazone
(H2L3)
It was prepared using the same procedure as described for H2L1 with 4-ethyl-3-thiosemicarbazide
(1.20 g, 0.01 mol) and 6-methyl-2-oxo-1,2-dihydroquinoline-3-carbaldehyde (1.87 g, 0.01 mol). A yellow
product was obtained. Yield 2.45 g (85%). MP: 265–267 ◦C. Elemental Analysis Anal. C 58.25%, H
5.56%, N 19.32%, S 11.06%. Calcd. for C14H16N4OS (MW 288.37) C 58.31%, H 5.59%, N 19.43%, S
11.12%. UV-visible (DMSO; λmax, nm): 265, 354, 410 (л→л*, n→л*). IR (KBr, cm−1) 3374, 3153 (s) ν(NH);
1648 (s) ν(C=O); 1540, 1603 (s) ν(C=N) + ν(C=C); 840 (m) ν(C=S). 1H NMR (DMSO-d6, 600 MHz) δ
11.64 (1H, s, N(2)-H), 11.95 (1H, s, N(3)-H), 8.60 (1H, s, N(4)-H), 8.29 (1H, s, C(1)-H), 8.62 (1H, s, C(6)-H),
7.24 (1H,d, J = 8.3 Hz, C(7)-H), 7.37 (1H,d, J = 8.3 Hz, C(8)-H), 7.48 (1H,s, C(10)-H), 2.36 (3H,s,C(11)-H),
3.64 (2H, q, J = 8.2 Hz, C(13)-H), 1.20 (3H,t, J = 8.2 Hz, C(14)-H). 13C{1H} NMR (DMSO-d6, 600 MHz) δ
137.1 (C-1), 125.8 (C-2), 161.3 (C-3), 137.4 (C-4), 119.5 (C-5), 135.0 (C-6), 115.6 (C-7), 132.7 (C-8), 131.8
(C-9), 128.3 (C-10), 20.9 (C-11), 177.2 (C-12), 38.7 (C-13), 15.0 (C-14). 15N NMR (DMSO-d6, 600 MHz) δ
317 (s, N(1)), 172 (d, J = 89 Hz, N(2)-H), 150 (d, J = 89 Hz, N(3)-H), 119 (t, J = 89 Hz, N(4)-H). ESI (H2L3
= C14H16N4OS) m/z 311 [H2L3Na]+ (100), 289 [H3L3]+ (10), 244 [H3L2–NH2Et]+ (5), 255 [H3L3–H2S]+
(15), 266 [H2L3Na–H2NEt]+ (10), 599 [2H2L3Na]+ (65), 887 [3H2L3Na]+ (35), 1175 [4H2L3Na]+ (50),
1463 [5H2L3Na]+ (70), 1750 [6H2L3Na]+ (55).
5.2.4. Synthesis of the Complex 1 (H2L1Cu)
A warm methanol solution (20 mL) containing H2L1 (130 mg, 0.5 mmol) was added to a methanol
solution (20 mL) of Cu(NO3)2.3H2O (121 mg, 0.5 mmol). The resulting greenish solution was refluxed
for 30 min. The solution was reduced to a small volume (3 mL), and by addition of Et2O a green
powder precipitated, which was filtered off, washed with Et2O and dried under vacuum. Yield 213 mg
(85%). Mp. 275–277 ◦C (dec). Elemental Analysis Anal. C 28.57%; H 3.55%, N 16.98%, S 6.28%. Calcd.
for [C12H12N4OSCu(H2O)3](NO3)2 (MW 501.89) C 28.71%, H 3.61%, N 16.74%, S 6.39%. UV-visible
(DMSO; λmax, nm; ε, cm−1M−1): 386 (19,020) (LMCT). IR (KBr disks, cm−1): 3376, 3138(s) ν(NH);
3266 (s) ν(NH2); 1637(s) ν(C=O); 1605, 1549 (s) ν(C=N) + ν(C=C); 825 (m) ν(C=S); 525 (w) ν(Cu-O);
469 (w) ν(Cu-N). ESI m/z 322 [HL1Cu]+ (100), 353 [HL1Cu+MeOH]+ (20), 644 [(HL1Cu)2]+ (30), 966
[(HL1Cu)3]+ (25), 1288 [(HL1Cu)4]+ (35), 1610 [(HL1Cu)5]+ (20), 1932 [(HL1Cu)6]+ (10).
5.2.5. Synthesis of the Complex 2 (H2L2Cu)
It was prepared by the same procedure as described for 1 using H2L2 (137 mg, 0.5 mmol) and
Cu(NO3)2.3H2O (121 mg, 0.5 mmol). Yield 219 mg (88%). Mp. 288–290 ◦C (dec). Elemental Analysis
Anal. C 31.39%, H 3.5%, N 17.00%, S 6.43%. Calcd. for [C13H14N4OSCu(H2O)2](NO3)2 (MW 497.90)
C 31.36%, H 3.64%, N 16.88%, S 6.44%. UV-visible (DMSO; λmax, nm; ε, cm−1M−1): 391 (22,530)
(LMCT). IR (KBr disks, cm−1): 3239 ν(NH); 1635(s) ν(C=O); 1605, 1548 (s) ν(C=N) + ν(C=C); 824 (m)
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ν(C=S); 523 (w) ν(Cu-O); 463 (w) ν(Cu-N). ESI m/z 336 [HL2Cu]+ (100), 367 [HL2Cu+MeOH]+ (15),
672 [(HL2Cu)2]+ (75), 1008 [(HL2Cu)3]+ (55), 1344 [(HL2Cu)4]+ (55), 1680 [(HL2Cu)5]+ (30).
5.2.6. Synthesis of the Complex 3 (H2L3Cu)
It was prepared by the same procedure as described for 1 using H2L3 (144 mg, 0.5 mmol) and
Cu(NO3)2.3H2O (121 mg, 0.5 mmol). Yield 210 mg (82%). Mp. 292–294 ◦C (dec). Elemental Analysis
Anal. C 32.55%, H 3.82%, N 16.28%, S 6.19%. Calcd. for [C14H16N4OSCu(H2O)2](NO3)2 (MW 511.93) C
32.84%, H 3.94%, N 16.42%, S 6.26%. UV-visible (DMSO; λmax, nm; ε, cm−1M−1): 392 (19,000) (LMCT).
IR (KBr disks, cm−1): 3435, 3210 (s) ν(NH); 1646(s) ν(C=O); 1608, 1547 (s) ν(C=N) + ν(C=C); 820 (m)
ν(C=S); 525 (w) ν(Cu-O); 463 (w) ν(Cu-N). ESI m/z 350 [HL3Cu]+ (100), 381 [HL3Cu+MeOH]+ (15),
700 [(HL3Cu)2]+ (90), 1050 [(HL3Cu)3]+ (50), 1400 [(HL3Cu)4]+ (30), 1750 [(HL3Cu)5]+ (15).
5.3. X-ray Crystallography
Single-crystal X-ray diffraction data of the complexes 1–3 were collected on GADDS (Bruker,
Madison, WI, USA) or on APEX II CCD (Bruker, Milan, Italy) diffractometers at 110(2) K. The extended
lists of crystallographic, experimental and data reduction parameters, refinement results and
geometrical parameters are given in the Supplementary Information (Tables S1–S17) and in the
deposited cif-files. CCDC 1,987,299, CCDC 841,988 and CCDC 841,992 contain the supplementary
crystallographic data for this paper. The data can be obtained free of charge from The Cambridge
Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures. The structures of the complexes
were solved by direct methods and refined by full matrix least-squares (the function minimized being
[w (Fo2–(1/k) Fc2)2]). The hydrogen atoms were either placed in calculated positions or found in Fourier
difference maps (in particular those of the water ligands). All non-hydrogen atoms were refined using
anisotropic displacement parameters, while hydrogens were refined using a riding model unless
otherwise specified.
Crystal Data for 1: C24H36Cu2N12O20S2 (M = 1003.85 g/mol): triclinic, space group P1 (no. 1),
a = 8.5216(3) Å, b = 10.0064(4) Å, c = 12.0178(5) Å, α = 110.055(2)◦, β = 110.055(2)◦, γ = 90.040(2)◦,
V = 954.56(6) Å3, Z = 1, T = 110(2) K, µ(CuKα) = 3.270 mm−1, Dcalc = 1.746 g/cm3, 21,621 reflections
measured (3.95◦ ≤ Θ ≤ 60.0◦), 5333 unique (Rint = 0.0472) which were used in all calculations. The final
R1 was 0.0268 (I > 2σ(I)), and wR2 was 0.0611 (all data).
Crystal Data for 2: C13H18CuN6O9S (M = 497.93 g/mol): triclinic, space group P-1 (no. 2),
a = 8.146(3) Å, b = 10.159(3) Å, c = 12.635(4) Å, α = 93.59(4)◦, β = 92.39(4)◦, γ = 112.15(4)◦,
V = 964.2(6) Å3, Z = 2, T = 110(2) K, µ(MoKα) = 1.303 mm−1, Dcalc = 1.715 g/cm3, 6853 reflections
measured (1.62◦ ≤Θ ≤ 25.25◦), 3485 unique (Rint = 0.0395) which were used in all calculations. The final
R1 was 0.0560 (I > 2σ(I)), and wR2 was 0.1588 (all data).
Crystal Data for 3: C29H40Cu2N12O17S2 (M = 1019.33 g/mol): triclinic, space group P-1 (no. 2),
a = 10.3073(5) Å, b = 13.3389(7) Å, c = 15.2916(8) Å, α = 109.017(4)◦, β = 94.252(4)◦, γ = 94.665(4)◦,
V = 1969.8(2) Å3, Z = 2, T = 110(2) K, µ(CuKα) = 3.123 mm-1, Dcalc = 1.720 g/cm3, 30,628 reflections
measured (3.53◦ ≤Θ ≤ 59.99◦), 5585 unique (Rint = 0.0677) which were used in all calculations. The final
R1 was 0.0484 (I > 2σ(I)), and wR2 was 0.1303 (all data).
5.4. Experiments with Human Cells
Cu(II) complexes were dissolved in DMSO just before the experiment, and a calculated amount of
drug solution was added to the cell growth medium until a final solvent concentration of 0.5% was
obtained, which had no detectable effects on the cell viability. Cisplatin and oxaliplatin were dissolved
in 0.9% sodium chloride solution. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
and cisplatin were obtained from Sigma Chemical Co, St. Louis, MO, USA.
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5.4.1. Cell Cultures
Human lung (A549), colon (LoVo and HCT-15) and pancreatic (BxPC3, PSN-1) carcinoma cell
lines, along with melanoma (A375) cells, were obtained from the American Type Culture Collection
(ATCC, Rockville, MD, USA). Embryonic kidney HEK293 cells were obtained from the European
Collection of Cell Cultures (ECACC, Salisbury, UK). A431 are human cervical carcinoma cells kindly
provided by Prof. F. Zunino (Division of Experimental Oncology B, Istituto Nazionale dei Tumori,
Milan, Italy). The 2008 cells and cisplatin-resistant variant, C13*, are human ovarian adenocarcinoma
cell lines that were kindly provided by Prof. G. Marverti (Dept. of Biomedical Science of Modena
University, Italy). The LoVo OXP cells were derived, using a standard protocol, by growing LoVo
cells in increasing concentrations of oxaliplatin and following nine months of selection of resistant
clones. Cell lines were maintained in the logarithmic phase at 37 ◦C in a 5% carbon dioxide atmosphere
using the following culture media containing 10% fetal calf serum (Euroclone, Milan, Italy), antibiotics
(50 units/mL penicillin and 50 µg/mL streptomycin) and 2 mM l-glutamine: i) RPMI-1640 medium
(Euroclone, Milan, Italy) for BxPC3, PSN-1, 2008 and C13* cells; ii) F-12 HAM′S (Sigma Chemical Co.,
Darmstadt, Germany) for A549, LoVo and LoVo OXP cells; and iii) DMEM for A375 and HEK293 cells.
5.4.2. Cytotoxic Activity
The growth inhibitory effect towards tumor cells was evaluated by means of the MTT assay.
Briefly, (3–8) × 103 cells/well, depending on the growth characteristics of the cell line, were seeded in
96-well microplates in growth medium (100 µL). After 24 h, the medium was removed and replaced
with fresh medium containing the compound to be studied at the appropriate concentration. Triplicate
cultures were established for each treatment. After 72 h, each well was treated with 10 µL of a 5 mg/mL
MTT saline solution, and following 5 h of incubation 100 µL of a sodium dodecylsulfate (SDS) solution
in 0.01 M HCl were added. After an overnight incubation, cell growth inhibition was detected by
measuring the absorbance of each well at 570 nm using a Bio-Rad 680 microplate reader (Bio-Rad
Laboratories, Milan, Italy). The mean absorbance for each drug dose was expressed as a percentage
of the absorbance of the control untreated well and plotted vs. the drug concentration. Data were
fitted to a dose–response curve and the IC50 values (the drug concentrations that reduce the mean
absorbance values at 570 nm to 50% of those of untreated cells’ control wells) were calculated with the
four-parameter logistic model (4-PL). The final value was the mean ± S.D. of at least three independent
experiments performed in triplicate.
5.4.3. Spheroid Cultures and Acid Phosphatase (APH) Assay
Spheroid cultures were obtained by seeding 2.5× 103 cancer cells/well in a round bottom non-tissue
culture treated 96-well plate (Greiner Bio-one, Kremsmünster, Austria) in phenol red free RPMI-1640
medium (Sigma Chemical Co., Darmstadt, Germany), containing 10% FCS and supplemented with
20% methyl cellulose stock solution. After 72 h, the medium was removed and replaced with fresh
medium containing the compound to be studied at the appropriate concentration. A modified APH
assay, which is based on the quantification of the cytosolic acid phosphatase activity, was used
for determining the cell viability in spheroids [121]. Triplicate cultures were established for each
treatment. After 72 h, each well was treated with 100 µL of the assay buffer (0.1 M sodium acetate,
0.1% Triton-X-100, supplemented with ImmunoPure p-nitrophenyl phosphate; Sigma Chemical Co.,
Darmstadt, Germany), and, following 3 h of incubation, 10 µL of 1 M NaOH solution were added.
The inhibition of the cell growth induced by the tested complexes was detected by measuring the
absorbance of each well at 405 nm, using a Bio-Rad 680 microplate reader. The mean absorbance for each
drug dose was expressed as a percentage of the control untreated well absorbance (T/C) and plotted vs.
the drug concentration. IC50 values (the drug concentrations that reduce the mean absorbance values
at 405 nm to 50% of those in the untreated control wells) were calculated by the four-parameter logistic
(4-PL) model. The evaluation was based on the means of at least four independent experiments.
Molecules 2020, 25, 1868 21 of 31
5.4.4. Cellular Accumulation of Cu
A375 cells (2× 106) were seeded in 75 cm2 flasks in growth medium (20 mL). After 24 h, the medium
was replaced and the cells were incubated for 12 or 24 h in the presence of the tested complexes.
Cell monolayers were washed twice with cold phosphate-buffered saline (PBS), harvested and counted.
Samples were subjected to three freeze–thaw cycles at −80 ◦C and were then vigorously vortexed.
The samples were treated with highly pure nitric acid (1 mL; Cu ≤ 0.005 mg kg−1, Trace-SELECT
Ultra, Sigma Chemical Co., Darmstadt, Germany) and transferred into a microwave Teflon vessel.
Subsequently, the samples were submitted to standard mineralization procedures. The samples were
analyzed for platinum by using a Varian AA Duo graphite furnace atomic absorption spectrometer
(Varian, Palo Alto, CA, USA) at the wavelength of 324 nm. The calibration curve was obtained using
known concentrations of standard solutions purchased from Sigma Chemical Co. (Sigma Chemical
Co., Darmstadt, Germany)
5.4.5. DNA Fragmentation
A375 cells (5 × 106) were seeded in 10 cm Petri dishes in 10 mL of culture medium. Subsequently,
cells were treated with tested complexes for 24 h. Nuclear DNA fragmentation (mono- and
oligo-nucleosome formation) was detected with the DNA damage ELISA kit (Enzo Life Sciences,
Farmingdale, NY, USA) according to the manufacturer’s instructions.
5.4.6. Reactive Oxygen Species (ROS) Production
The production of ROS was measured in A375 cells (104 per well) grown for 24 h in a 96-well plate
in RPMI medium without phenol red (Sigma Chemical Co., Darmstadt, Germany). Cells were then
washed with PBS and loaded with 10 µM 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein
diacetate acetyl ester (CM–H2DCFDA) (Molecular Probes-Invitrogen, Eugene, OR) for 25 min, in the
dark. Afterwards, cells were washed with PBS and incubated with increasing concentrations of tested
complexes. The fluorescence increase was estimated utilizing the wavelengths of 485 nm (excitation)
and 527 nm (emission) in a Fluoroskan Ascent FL (Labsystem, Finland) plate reader. Antimycin (3 µM,
Sigma Chemical Co., Darmstadt, Germany), a potent inhibitor of Complex III in the electron transport
chain, was used as the positive control.
5.4.7. Transmission Electron Microscopy (TEM) Analyses
About 106 A375 cells were seeded in 24-well plates and, after 24 h incubation, treated with
the tested compounds and incubated for additional 24 h. Cells were then washed with cold PBS,
harvested and directly fixed with 1.5% glutaraldehyde buffer with 0.2 M sodium cacodylate, pH 7.4.
After washing with buffer and after post-fixation with 1% OsO4 in 0.2 M cacodylate buffer, specimens
were dehydrated and embedded in epoxy resin (Epon Araldite from Sigma Chemical Co., Darmstadt,
Germany). Sagittal serial sections (1 µm) were counterstained with toluidine blue; thin sections (90 nm)
were given contrast by staining with uranyl acetate and lead citrate. Micrographs were taken with a
Hitachi H-600 electron microscope (Hitachi, Tokyo, Japan) operating at 75 kV. All photos were typeset
in Corel Draw 11.
5.4.8. Statistical Analysis
All the values are the means ± SD of no fewer than three measurements. Multiple comparisons
were made by ANOVA followed by a Tukey–Kramer multiple comparison test (** p < 0.01; * p < 0.05).
6. Conclusions
In order to shed more light on the widely reported antimicrobial and antiproliferative activity of
TSCs, the electronic and steric properties of the X, Z and Y moieties (Chart 1) have been previously
investigated, also through computational analysis [122] based on Triapine as the model. In particular,
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some aspects appeared to be relevant for biological activity, such as: chelating ability, the presence
of nitrogen atoms with hydrogen bond donor (NH) or acceptor (N-N=C) properties, the presence
of a C=S moiety as a hydrogen bond donor, the presence of other hydrogen bond acceptor atoms
(i.e., F, cfr. Fluorouracil), a suitable o/w partition coefficient to ensure the passive diffusion of the
compound through the cell membrane [123], and additional hydrophobic moieties able to be involved
in pi-pi interactions with biomolecules modifying the biological activity. The coordination of TSCs by a
metal ion, in particular copper, can confer to the molecule specific chemical properties which in turn
modulate intrinsic characteristics (such as cyclization and redox potential) as well as the biological fate
(such as distribution, and target and off-target reactivity) [124,125].
Concerning the copper complexes considered in this paper, their biological activity is characterized
by some peculiar properties:
1. the IC50 values against some human tumor cell lines derived from solid tumors are significantly
lower (at nanomolar level) than those elicited by cisplatin; it is worth noting that a higher
cytotoxicity, with respect to the reference compound, was retained in the 3D spheroids of colon
cancer and melanoma cells, which is undoubtedly more predictive of in vivo results than standard
2D monolayer cultures;
2. the remarkable cancer cell-killing effect is consistent with their ability to accumulate in human
melanoma cells, which may be favored by a suitable balance between the cationic nature of the
overall complexes [126] and the hydrophobicity of the pro-ligand skeleton;
3. complexes 1–3 are markedly effective against human cancer cells with a developed resistance to
cisplatin, with an RF factor of 1,8, 1.1 and 1.6 for 1, 2 and 3, respectively;
4. complexes 2 and 3 exhibit a significant preferential cytotoxicity against human melanoma cancer
cells with respect to non-cancerous HEK293 cells;
5. Despite other copper thiosemicarbazone complexes having been shown to be primarily localized
in mitochondria, thus compromising mitochondrial functions [127], TEM images of treated
A375 cells indicated that mitochondria were quite conserved and that no alterations in internal
structures were detected. Hence, the modest ROS formation induced by the tested complexes
do not contribute in a significant manner to the DNA damage induced by the tested complexes.
In addition, the morphological changes such as cell shrinkage and the formation of apoptotic
bodies suggest the occurrence of the apoptotic process, likely due to the induction of DNA
damage as revealed by DNA fragmentation. Further studies will be performed in order to better
characterize the mechanism of cell death induced by the tested complexes.
In summary, a more promising in vitro antiproliferative activity for complexes 2 (bearing the
-NHMe moiety) and 3 (bearing the -NHEt moiety) has been observed with respect to complex 1 (with
the -NH2 group). It is worth noting that the presence of the -NHEt group within a thiosemicarbazone
structure was reported to improve the biological activity, including anticancer, antifungal and
antibacterial action, in other TSC Cu(II) [57,93,128–130] complexes and in Ru(II) TSC derivatives [131].
Overall, the results reported here can open interesting possibilities for the design of optimized
metal-based thiosemicarbazone anticancer agents: further studies to better characterize the potential
of this class of copper(II) complexes as anticancer agents are ongoing.
Supplementary Materials: The Supplementary Materials are available online. Figure S1: Cyclic voltammograms
for H2L1 (top) and H2L3 (bottom). Figure S2: Cyclic voltammograms for 1 (top; C = 3.06 × 10−3 M) and for 3
(bottom; C = 3.02 × 10−3 M). Figure S3: ORTEP view of compound 2 with the full numbering scheme. Figure S4:
Packing view of 2 showing the pi-pi stacking between the aromatic part of the ligands. Figure S5: View of the
molecular packing in 2 along the a axis. Figure S6: Selected short intermolecular hydrogen bond interactions
in 2. Table S1: Crystal data and structure refinement for 2. Table S2: Atomic coordinates (×104) and equivalent
isotropic displacement parameters (Å2 × 103) for 2. Table S3: Anisotropic displacement parameters (Å2 × 103)
for 2. Table S4: Hydrogen coordinates (×104) and isotropic displacement parameters (Å2 × 103) for 2. Table S5:
Bond lengths [Å] and angles [◦] for 2. Table S6: Torsion angles [◦] for 2. Table S7: Least squares planes for 2.
Figure S7: ORTEP view of compound 1 showing the two independent molecules in the unit cell (1a (Cu2) and 1b
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(Cu1)) with the numbering scheme. Figure S8: Molecular Packing of 1. Figure S9: Molecular Packing of 1 down
the b axis. Figure S10: Selected short H-bonding interactions in 1. Figure S11: A view of the short H-bonding
interactions involving the NH2 groups (N4 and N8, respectively). Table S8: Crystal data and structure refinement
for 1. Table S9: Atomic coordinates (×104) and equivalent isotropic displacement parameters (Å2 × 103) for 1.
Table S10: Bond lengths [Å] and angles [◦] for 1. Table S11: Anisotropic displacement parameters (Å2 × 103) for
1. Table S12: Hydrogen coordinates (×104) and isotropic displacement parameters (Å2 × 103) for 1. Figure S12:
ORTEPs with the numbering schemes of 3a, 3b, nitrate counter ions and clathrated water molecule. Figure S13:
ORTEP view of the unit cell of 3. Figure S14: Molecular packing of 3. Figure S15: Molecular packing of 3. Figure
S16: Selected short H-bonding interactions in 3. Table S13 Crystal data and structure refinement for 3. Table S14:
Atomic coordinates (×104) and equivalent isotropic displacement parameters (Å2 × 103) for 3. Table S15: Bond
lengths [Å] and angles [◦] for 3. Table S16: Anisotropic displacement parameters (Å2 × 103) for 3. Table S17:
Hydrogen coordinates (×104) and isotropic displacement parameters (Å2 × 103) for 3. Table S18: Cytotoxicity in
A375 cancer cells. Figure S17 Dose-response curves for cell viability assessed in A375 cells.
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